The surgical equipment manufacturer's second quarter report surprised analysts, setting Intuitive up for a strong second half.
Positive readings from the biotech giant's Alzheimer's drug could drive the stock to as high as $393.
The drug company received a preliminary injunction blocking Dr. Reddy's Laboratories from selling its opioid treatment drug.
The company sees the market for lung cancer detection as being worth $4.7 billion annually.
Let's review what happened on Monday.
The deal is part of Axovant's strategy to focus on neurological gene therapies.
Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.
The company's drug showed promising results versus a placebo in a Phase 2 trial.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.